Teleflex (NYSE:TFX) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Teleflex (NYSE:TFX) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other brokerages also recently issued reports on TFX. Needham & Company LLC lifted their price target on shares of Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Truist Financial increased their price objective on shares of Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research report on Thursday, December 18th. Royal Bank Of Canada lifted their price objective on shares of Teleflex from $115.00 to $125.00 and gave the stock a “sector perform” rating in a research report on Friday, February 27th. Wells Fargo & Company boosted their target price on shares of Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Finally, Zacks Research lowered Teleflex from a “hold” rating to a “strong sell” rating in a report on Monday, March 2nd. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Teleflex has an average rating of “Hold” and an average target price of $140.83.

Teleflex Price Performance

Shares of NYSE TFX opened at $113.61 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.54 and a quick ratio of 2.01. The company has a market cap of $5.02 billion, a price-to-earnings ratio of -5.53, a price-to-earnings-growth ratio of 0.71 and a beta of 0.87. The stock’s 50-day moving average is $110.79 and its two-hundred day moving average is $118.49. Teleflex has a 1-year low of $100.18 and a 1-year high of $143.32.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The company had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $912.57 million. During the same quarter in the previous year, the business posted $3.89 EPS. The business’s quarterly revenue was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Friday, March 6th. Teleflex’s payout ratio is currently -6.62%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. increased its position in shares of Teleflex by 23.6% during the second quarter. Russell Investments Group Ltd. now owns 83,388 shares of the medical technology company’s stock worth $9,870,000 after purchasing an additional 15,935 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Teleflex by 24.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 188,208 shares of the medical technology company’s stock valued at $23,029,000 after purchasing an additional 37,539 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Teleflex by 113.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 58,047 shares of the medical technology company’s stock valued at $7,366,000 after purchasing an additional 30,912 shares during the period. Creative Planning boosted its position in shares of Teleflex by 76.5% in the 2nd quarter. Creative Planning now owns 10,338 shares of the medical technology company’s stock valued at $1,224,000 after purchasing an additional 4,480 shares during the period. Finally, Savant Capital LLC grew its stake in Teleflex by 81.0% during the 3rd quarter. Savant Capital LLC now owns 18,248 shares of the medical technology company’s stock worth $2,233,000 after buying an additional 8,166 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.